Langerhans cell histiocytosis is a rare hematologic disorder and patients who fail first-line treatment have a poor prognosis, and require more intensive treatment. We present an infant diagnosed with multisystem Langerhans cell histiocytosis refractory to multimodal therapy who was successfully treated with cyclosporine. Cyclosporine might be an effective alternative drug as nonmyelosuppressive rescue therapy for multiple relapsed-refractory Langerhans cell histiocytosis that has not achieved remission with cladribine and cytarabine therapy.
EmileJFAblaOFraitagS, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood2016; 127: 2672–2681.
FureuMKatzS. The effect of cyclosporin on epidermal cells: i: cyclosporine inhibits accessory cell functions of epidermal Langerhans cells in vitro. J Immunol1988; 140: 4139–4143.
AricòMColellaRConterV, et al. Cyclosporine therapy for refractory Langerhans cell histiocytosis. Med Pediatr Oncol1995; 25: 12–16.
6.
KörholzDJanssenGGöbelU. Treatment of relapsed Langerhans cell histiocytosis by cyclosporine A combined with etoposide and prednisone. Pediatr Hematol Oncol1997; 14: 443–449.
7.
MinkovMGroisNBroadbentV, et al. Cyclosporine A therapy for multisystem Langerhans cell histiocytosis. Med Pediatr Oncol1999; 33: 482–485.
8.
ZellerBStorm-MathisenISmevikB, et al. Multisystem Langerhans-cell histiocytosis with life-threatening pulmonary involvement: good response to cyclosporine A. Med Pediatr Oncol2000; 35: 438–442.
